MEREO BIOPHARMA (MREO)
(Delayed Data from NSDQ)
$1.63 USD
-0.03 (-1.81%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $1.67 +0.04 (2.45%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Mereo BioPharma Group plc - Sponsored ADR's return on equity, or ROE, is -69.34% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.42%. While this shows that MREO has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
MREO 1.63 -0.03(-1.81%)
Will MREO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MREO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MREO
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End
MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock?
MREO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for MREO
Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks
12 Health Care Stocks Moving In Thursday's Intraday Session
Crude Oil Down Over 2%; Delta Air Lines Posts Upbeat Earnings
Trump declares 50% tariff on copper, Brazil: Morning Buzz
US Stocks Mixed; Initial Jobless Claims Fall